
Education and Training
- Resident, Internal Medicine, Duke University School of Medicine, 2008 - 2011
- M.D., University of North Dakota, School of Medicine and Health Sciences, 2008
Grants
- A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia
- Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- Phase 2 study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3ss) inhibitor, as a single agent or combined with Ruxolitinib, in patients with myelofibrosis
- COVID-19 Phase 3 Assess Efficacy of Ruxolitinib
- BBI Ph1 TP-3654 and Ruxolitinb in patients with Intermediate and High Risk Myelofibrosis
- A Phase 1b, multicenter, open-label dose escalation and expansion platform study of select combinations in adult patients with myelofibrosis
- Targeting beta-arrestins in myeloid malignancies